Announcement

Collapse
No announcement yet.

Rev Med Virol . Epitope mapping of neutralising anti-SARS-CoV-2 monoclonal antibodies: Implications for immunotherapy and vaccine design

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts

  • Rev Med Virol . Epitope mapping of neutralising anti-SARS-CoV-2 monoclonal antibodies: Implications for immunotherapy and vaccine design


    Rev Med Virol


    . 2022 Apr 8;e2347.
    doi: 10.1002/rmv.2347. Online ahead of print.
    Epitope mapping of neutralising anti-SARS-CoV-2 monoclonal antibodies: Implications for immunotherapy and vaccine design


    Somayeh Ghotloo 1 , Faezeh Maghsood 2 , Forough Golsaz-Shirazi 2 , Mohammad Mehdi Amiri 2 , Christiane Moog 3 , Fazel Shokri 2



    Affiliations

    Abstract

    Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of the coronavirus disease 2019 (COVID-19) pandemic. This disease has currently affected more than 346 million people and resulted in more than 5.5 million deaths in many countries. Neutralising monoclonal antibodies (MAbs) against the SARS-CoV-2 virus could serve as prophylactic/therapeutic agents in COVID-19 infection by providing passive protection against the virus in individuals. Until now, no Food and Drug Administration/European Medicines Agency-approved neutralising MAb against SARS-CoV-2 virus exists in the market, though a number of MAbs have been authorised for emergency use. Therefore, there is an urgent need for development of efficient anti-SARS-CoV-2 neutralising MAbs for use in the clinic. Moreover, neutralising anti-SARS-CoV-2 MAbs could be used as beneficial tools for designing epitope-based vaccines against the virus. Given that the target epitope of a MAb is a crucial feature influencing its neutralising potency, target epitopes of neutralising anti-SARS-CoV-2 MAbs already reported in the literature and reactivity of these MAbs with SARS-CoV-2 variants are reviewed herein.

    Keywords: COVID-19; RBD; SARS-CoV-2 virus; epitope mapping; immunotherapy; neutralising monoclonal antibody.

Working...
X